BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 24708055)

  • 1. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of medical treatments for benign prostatic hyperplasia on sexual function.
    Giuliano F
    BJU Int; 2006 Apr; 97 Suppl 2():34-8; discussion 44-5. PubMed ID: 16507052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
    Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
    Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; de La Taille A; Giuliano F; Desgrandchamps F; Doridot G
    Prog Urol; 2015 Mar; 25(3):115-27. PubMed ID: 25605342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Rosen RC; Fitzpatrick JM;
    BJU Int; 2009 Oct; 104(7):974-83. PubMed ID: 19426189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
    Roehrborn CG; Manyak MJ; Palacios-Moreno JM; Wilson TH; Roos EPM; Santos JC; Karanastasis D; Plastino J; Giuliano F; Rosen RC
    BJU Int; 2018 Apr; 121(4):647-658. PubMed ID: 29044968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride for benign prostatic hyperplasia.
    Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Rosen RC; Giuliano F; Carson CC
    Eur Urol; 2005 Jun; 47(6):824-37. PubMed ID: 15925080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-alpha reductase inhibitors and erectile dysfunction: the connection.
    Erdemir F; Harbin A; Hellstrom WJ
    J Sex Med; 2008 Dec; 5(12):2917-24. PubMed ID: 19090946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis.
    Guo J; Tang R
    Medicine (Baltimore); 2021 Aug; 100(33):e26955. PubMed ID: 34414962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.